Price Chart

Key Stats

Customize
Expense Ratio Discount or Premium to NAV Total Assets Under Management 30-Day Average Daily Volume
0.56% 0.14% 206.39M 157341.8
Dividend Yield Turnover Ratio 1 Year Fund Level Flows Max Drawdown (All)
0.00% 29.76% 170.25M Upgrade

Basic Info

Investment Strategy
The investment seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive Genomics Index ("underlying index"). The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies that are positioned to benefit from further advances in the field of genomic science and biotechnology, as well as applications thereof (collectively, "Genomics & Biotechnology Companies"), as defined by Solactive AG, the provider of the underlying index. The fund is non-diversified.
General
Security Type Exchange-Traded Fund
Equity Style Mid Cap/Growth
Fixed Income Style --
Broad Asset Class Sector Equity
Broad Category Equity
Category Name Health
Category Index S&P 1500 Health Care TR
Prospectus Objective Specialty - Unaligned
Fund Owner Firm Name Global X Funds
Prospectus Benchmark Index
Solactive Genomics Index NR USD 100.0%
Broad Asset Class Benchmark Index
^MSWNTR 100.0%
Manager Tenure
Nam To 1.99 yrs
Wayne Xie 1.99 yrs
Kimberly Chan 1.81 yrs
John Belanger 0.25 yrs
Vanessa Yang 0.25 yrs

Net Fund Flows Versus Category

View Net Fund Flows. Upgrade now.
1M
3M
6M
YTD
1Y
3Y
5Y
10Y
 
80.00B
60.00B
40.00B
20.00B
0
-20.00B
1 Month
% Rank: --
-- Category Low
-- Category High
1 Year
% Rank: 17
170.25M
-4.178B Category Low
8.066B Category High
3 Months
% Rank: --
-- Category Low
-- Category High
3 Years
% Rank: --
-- Category Low
-- Category High
6 Months
% Rank: --
-- Category Low
-- Category High
5 Years
% Rank: --
-- Category Low
-- Category High
YTD
% Rank: --
-- Category Low
-- Category High
10 Years
% Rank: --
-- Category Low
-- Category High
As of March 31, 2021

Performance Versus Category

 
20%
15%
10%
5%
0
View Category Returns. Upgrade now.
Name
1M
3M
YTD
1Y
3Y
5Y
10Y
15Y
Total Return (Price)
--
--
--
--
--
--
--
--
Total Return (NAV)
--
--
--
--
--
--
--
--
Category Rtn. (NAV)
--
--
--
--
--
--
--
--
% Rank in Cat (NAV)
--
--
--
--
--
--
--
--
As of April 09, 2021. Returns for periods of 1 year and above are annualized.

Annual Total Returns Versus Peers

Edit comparables
Name
2014
2015
2016
2017
2018
2019
2020
YTD
--
--
--
--
--
--
51.52%
-6.77%
4.94%
-0.87%
7.51%
22.40%
-8.71%
27.67%
15.90%
8.64%
--
--
--
--
--
--
54.29%
-3.03%
36.34%
1.73%
-22.90%
22.28%
-0.19%
18.65%
25.66%
4.01%
--
--
--
--
--
--
65.01%
2.74%
30.34%
10.33%
-15.01%
16.46%
-10.69%
26.34%
22.13%
4.26%
As of April 09, 2021.

Fundamentals

General
Distribution Yield Upgrade
Dividend Yield TTM (4-9-21) 0.00%
30-Day SEC Yield (3-31-21) Upgrade
7-Day SEC Yield --
Number of Holdings Upgrade
Stock
Weighted Average PE Ratio --
Weighted Average Price to Sales Ratio Upgrade
Weighted Average Price to Book Ratio Upgrade
Weighted Median ROE Upgrade
Weighted Median ROA Upgrade
Forecasted Dividend Yield Upgrade
Forecasted PE Ratio Upgrade
Forecasted Price to Sales Ratio Upgrade
Forecasted Price to Book Ratio Upgrade
As of April 08, 2021

Growth Estimates

Forecasted 5 Yr Earnings Growth Upgrade
Forecasted Book Value Growth Upgrade
Forecasted Cash Flow Growth Upgrade
Forecasted Earnings Growth Upgrade
Forecasted Revenue Growth Upgrade
As of April 08, 2021

Asset Allocation

As of April 08, 2021.
Type % Net % Long % Short
Cash -0.02% Upgrade Upgrade
Stock 100.0% Upgrade Upgrade
Bond 0.00% Upgrade Upgrade
Convertible 0.00% Upgrade Upgrade
Preferred 0.00% Upgrade Upgrade
Other 0.00% Upgrade Upgrade

Top 10 Holdings

Name % Weight Price % Change
Pacific Biosciences of California Inc 6.00% 32.16 -3.97%
Natera Inc 5.14% 104.98 -0.69%
Illumina Inc 4.36% 403.37 -0.09%
Agilent Technologies Inc 4.29% 131.91 0.93%
CRISPR Therapeutics AG 4.22% 115.74 -3.85%
Intellia Therapeutics Inc 3.97% 70.64 -3.34%
CareDx Inc 3.85% 71.75 -1.48%
Alnylam Pharmaceuticals Inc 3.80% 138.23 -3.00%
Ultragenyx Pharmaceutical Inc 3.74% 103.48 -2.88%
Arrowhead Pharmaceuticals Inc 3.60% 62.15 -2.45%

News

Headline
Wire
Time (ET)

Basic Info

Investment Strategy
The investment seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive Genomics Index ("underlying index"). The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies that are positioned to benefit from further advances in the field of genomic science and biotechnology, as well as applications thereof (collectively, "Genomics & Biotechnology Companies"), as defined by Solactive AG, the provider of the underlying index. The fund is non-diversified.
General
Security Type Exchange-Traded Fund
Equity Style Mid Cap/Growth
Fixed Income Style --
Broad Asset Class Sector Equity
Broad Category Equity
Category Name Health
Category Index S&P 1500 Health Care TR
Prospectus Objective Specialty - Unaligned
Fund Owner Firm Name Global X Funds
Prospectus Benchmark Index
Solactive Genomics Index NR USD 100.0%
Broad Asset Class Benchmark Index
^MSWNTR 100.0%
Manager Tenure
Nam To 1.99 yrs
Wayne Xie 1.99 yrs
Kimberly Chan 1.81 yrs
John Belanger 0.25 yrs
Vanessa Yang 0.25 yrs

Fundamentals

General
Distribution Yield Upgrade
Dividend Yield TTM (4-9-21) 0.00%
30-Day SEC Yield (3-31-21) Upgrade
7-Day SEC Yield --
Number of Holdings Upgrade
Stock
Weighted Average PE Ratio --
Weighted Average Price to Sales Ratio Upgrade
Weighted Average Price to Book Ratio Upgrade
Weighted Median ROE Upgrade
Weighted Median ROA Upgrade
Forecasted Dividend Yield Upgrade
Forecasted PE Ratio Upgrade
Forecasted Price to Sales Ratio Upgrade
Forecasted Price to Book Ratio Upgrade
As of April 08, 2021

Growth Estimates

Forecasted 5 Yr Earnings Growth Upgrade
Forecasted Book Value Growth Upgrade
Forecasted Cash Flow Growth Upgrade
Forecasted Earnings Growth Upgrade
Forecasted Revenue Growth Upgrade
As of April 08, 2021

Fund Details

Key Dates
Inception Date 4/5/2019
Last Annual Report Date 11/30/2020
Last Prospectus Date 4/1/2021
Attributes
Enhanced Index Fund No
Index Fund Yes
Inverse Fund No
Leveraged Fund No
Fund of Funds No
Currency Hedged Fund No
Synthetic Replication Fund No
Has Dividend Investment Plan No
Socially Responsible Fund No

News

Headline
Wire
Time (ET)